Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that the Company will present positive data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL. NDV-3 is a prophylactic vaccine being developed for Candida and Staphylococcus aureus (including methicillin-resistant S. aureus, or MRSA). NDV-3 is the first vaccine to demonstrate preclinical "cross-kingdom" protective efficacy against both fungal and bacterial pathogens. NovaDigm will present Phase 1 safety and immunogenicity data for the vaccine, as well as preclinical data in a model of vulvovaginal candidiasis (VVC).

The Phase 1 data and preclinical VVC data will be presented on Sunday, September 18, 2011 from 11:15 AM - 1:15 PM in poster session 097: Vaccines and Immunomodulators:

• G1-759/242 - A Phase 1 Clinical Evaluation of NDV-3, a Vaccine to Prevent Disease caused by Candida spp. and Staphylococcus aureus, to be presented by Dr. John Hennessey, Vice President of R&D for NovaDigm.
• G1-768/251 - NDV-3 Protects Mice From Vulvovaginal Candidiasis Through T- and B-Cell Immune Response, to be presented by Dr. Ashraf Ibrahim, Professor of Medicine, David Geffen School of Medicine at UCLA, and Division of Infectious Diseases, Department of Medicine, Harbor-UCLA Medical Center. Dr. Ibrahim is one of the scientific founders of NovaDigm.